ImmunityBio (IBRX) Lawsuit: What Investors Need to Know
Securities fraud class action lawsuits can have significant impacts on investors, and ImmunityBio (NASDAQ: IBRX) is now at the center of such a case. If you acquired IBRX securities between January 19, 2026, and March 24, 2026, you may be affected by recent legal actions stemming from allegations of misleading statements regarding the company’s leading product, Anktiva.
Overview of the ImmunityBio Securities Lawsuit
Kessler Topaz Meltzer & Check, LLP (KTMC), a nationally recognized law firm specializing in securities fraud class action lawsuits, has announced legal proceedings against ImmunityBio, Inc. The suit was filed on behalf of investors who purchased or acquired ImmunityBio securities within the specified class period. The complaint, currently pending in the United States District Court for the Central District of California, alleges that ImmunityBio made material misstatements and omissions about the business, particularly related to its lead biologic product, Anktiva.
Investors should note the deadline to seek lead plaintiff status is May 26, 2026. The outcome of this securities fraud class action lawsuit could influence potential recoveries for those who suffered losses during the class period.
Key Allegations in the Securities Fraud Class Action
The core of the ImmunityBio securities lawsuit revolves around accusations that company executives misrepresented critical information about Anktiva. Specifically, the complaint alleges that:
- Claims made by ImmunityBio regarding Anktiva as a cancer vaccine were false.
- The Executive Chairman and Global Scientific and Medical Officer overstated Anktiva’s capabilities.
- These statements led to artificially positive perceptions about the company’s business and prospects.
On March 24, 2026, Bloomberg reported that the U.S. Food and Drug Administration (FDA) had issued a warning letter to ImmunityBio after inaccurate claims were made about Anktiva, including statements that the drug could “cure and even prevent all cancer.” The FDA determined these statements were not only misleading but also violated the Federal Food, Drug, and Cosmetic Act. Following this news, ImmunityBio’s stock price dropped by 21.12%, closing at $7.42 per share.
What Steps Can IBRX Investors Take?
If you suffered losses after investing in ImmunityBio during the class period, you have several options. The securities fraud class action lawsuit allows you to seek appointment as lead plaintiff, which gives you the opportunity to help direct the litigation on behalf of all affected investors. The lead plaintiff is typically the investor or group with the largest financial interest and who is most representative of the class.
To become a lead plaintiff, you must file by May 26, 2026. Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation. Representation is provided on a contingency fee basis, meaning you only pay if there is a recovery. Importantly, choosing not to serve as a lead plaintiff does not affect your ability to participate in any potential recovery resulting from the lawsuit.
About Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is a leading U.S. law firm focused on representing investors in securities fraud class action lawsuits and global investor protection. The firm has a strong track record, having secured more than $25 billion in recoveries for clients and investor classes. KTMC represents both individual and institutional investors, including pension funds and asset managers, and has received numerous industry accolades for its work in securities litigation.
The firm’s offices are located in Pennsylvania and California, but it represents clients worldwide. For more information or to discuss your legal rights as an ImmunityBio investor, you can contact attorney Jonathan Naji, Esq. at (484) 270-1453 or visit the firm’s website.
Conclusion: Protecting Your Rights in the Securities Fraud Class Action Lawsuit
The ImmunityBio (IBRX) securities fraud class action lawsuit highlights the importance of transparency and accountability in public companies. If you invested in IBRX during the class period and experienced losses, it is critical to understand your rights and the legal remedies available through this securities fraud class action lawsuit. Contacting an experienced law firm like KTMC can help you navigate the process and maximize your chances of recovery.
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.